Sonodynamic-chemotherapy synergy with chlorin e6-based carrier-free nanoparticles for non-small cell lung cancer

Shuangyu Tian,Jinghang Li,Dongdong Wang,Yingchao Han,Honglian Dai,Lesan Yan
DOI: https://doi.org/10.1039/d4tb00009a
IF: 7.571
2024-03-16
Journal of Materials Chemistry B
Abstract:Sonodynamic therapy (SDT), an emerging cancer treatment with significant potential, offers the advantages of non-invasiveness and deep tissue penetrability. The method involves activating sonosensitizers with ultrasound to generate reactive oxygen species (ROS) capable of eradicating cancer cells, addressing the challenge faced by photodynamic therapy (PDT) where conventional light sources struggle to penetrate deep tissues, impacting treatment efficacy. This study addresses prevalent challenges in numerous nanodiagnostic and therapeutic agents, such as intricate synthesis, poor repeatability, low stability, and high cost, by introducing a streamlined one-step assembly method for nanoparticle preparation. Specifically, the sonosensitizer Chlorin e6 (Ce6) and the chemotherapy drug erlotinib are effortlessly combined and self-assembled under sonication, yielding carrier-free nanoparticles (EC-NPs) for non-small cell lung cancer (NSCLC) treatment. The resulting EC-NPs exhibit optimal drug loading capacity, a simplified preparation process, and robust stability both in vitro and in vivo , owing to their carrier-free characteristics. Under the synergistic treatment of sonodynamic therapy and chemotherapy, EC-NPs induce an excess of reactive oxygen in tumor tissue, prompting apoptosis of cancer cells and reducing their proliferative capacity. Both in vitro and in vivo experiments demonstrate superior therapeutic effects of EC-NPs under ultrasound conditions compared to free Ce6. In summary, our research findings highlight that the innovatively designed carrier-free sonosensitizer EC-NPs present a therapeutic option with commendable efficacy and minimal side effects.
materials science, biomaterials
What problem does this paper attempt to address?
This paper focuses on the development of a novel one-step assembly method for preparing carrier-free nanoparticles (EC-NPs) for the treatment of non-small cell lung cancer (NSCLC). The current challenges mentioned in the study include complex synthesis process, poor repeatability, low stability, and high cost. The paper proposes an innovative strategy to easily combine and self-assemble the photosensitizer chlorin e6 (Ce6) with the chemotherapy drug erlotinib under ultrasound, forming carrier-free nanoparticles to overcome the limited depth of light penetration in photodynamic therapy (PDT). SDT utilizes ultrasound to activate the photosensitizer and generate reactive oxygen species (ROS) that can eliminate cancer cells, while PDT is limited by the inability of light to penetrate deep into tissues. EC-NPs have optimized drug loading capacity, simplified preparation process, and strong stability in vitro and in vivo. Through the synergistic effect of sonodynamic therapy and chemotherapy, EC-NPs can generate excessive ROS in tumor tissues, induce cancer cell apoptosis, and reduce their proliferative ability. Both in vitro and in vivo experiments have shown that EC-NPs demonstrated superior therapeutic effects compared to free Ce6 under ultrasound conditions. Furthermore, the paper discusses the role of erlotinib as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which can block signaling pathways, inhibit tumor growth, and potentially trigger cell apoptosis. EC-NPs utilize carrier-free characteristics to achieve effective delivery through passive targeting enhanced permeability and retention effect (EPR). The research methods section provides detailed descriptions of the preparation, characterization, stability, ROS generation, blood compatibility, cellular uptake, intracellular ROS detection, MTT assay, cell apoptosis analysis, and in vivo experiments of EC-NPs. These experimental results demonstrate the potential of EC-NPs in the treatment of NSCLC, with good efficacy and low side effects.